Introduction
To best achieve complete occlusion of aneurysms treated with flow diverters (FDs), devices must be accurately sized to precisely match the parent vessel diameter. Porosity is lowest for a Pipeline embolization device (PED) as the expanded diameter of the device approaches its labeled diameter. 1 Appropriately sized PEDs will thus have maximal coverage over the aneurysm neck and will be more likely to induce aneurysm thrombosis. Catheterization for diagnostic angiography can cause vasospasm that may affect vessel measurements. 2 Such catheter-induced vasospasm (CIV) can be ameliorated with intra-arterial infusion of a calcium channel blocker (CCB). 3, 4 This study evaluates the effects of CCB infusion on angiographic measurements in patients treated with PEDs, investigating the impact on the final diameter of the device following deployment and subsequent occlusion.
Materials and methods
According to an institutional review board (IRB)approved protocol, retrospective analysis was performed of prospectively maintained procedure records to identify patients with aneurysms treated with PEDs. In all patients, pre-treatment measurements were recorded for vessel diameter of the future distal and proximal landing zones, as well as maximum and minimum diameters between these segments. Additionally, the size of the aneurysm and morphology were noted. Morphology was classified as saccular vs. fusiform, lobulated vs. not, and projecting in the direction of shear stress vs. not. Post-treatment measurements of the FD itself following deployment were recorded at the distal and proximal ends in addition to maximum and minimum diameters throughout the length of the device. When a CCB was infused prior to treatment, post-infusion pre-treatment measurements were recorded. All measurements were performed after calibrating to a catheter included on the image. Rates of occlusion and O'Kelly-Marotta (OKM) angiographic score were noted for all patients. 5 A representative case is provided in Figure 1 . For classification as an ordinal variable, OKM scores were converted from a hierarchical alphanumeric scale to a 10-point scale. Independent-sample two-tailed T-tests were performed to assess for differences in pre-and posttreatment measurements, rates of occlusion, and OKM score immediately after deployment and at first follow-up. Follow-up times were noted.
Results
Twenty-eight PEDs were deployed to treat 25 aneurysms in 24 patients. Patient demographics and FD sizes for the two groups are summarized in Table 1 . CCB infusion was performed prior to deployment of 12 (42.9%) devices. The changes in measurements noted after CCB infusion are summarized in Table 2 . 
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Discussion
The decreased porosity produced by the increased metallic coverage of FDs compared to conventional stents allow for stagnation within and eventual occlusion of aneurysms. The true porosity of an FD when deployed in a vessel depends on the labeled diameter of the device and the diameter of the vessel into which it expands. As the diameter of expansion for a PED increases, the device foreshortens, and the metallic coverage per area increases ( Figure 2 ). 1 Additionally, the complex structure of intracranial vasculature leads to variability in the extent of expansion. Two considerations are most important for selecting the appropriate FD size. First, the device should be selected so the device will appose the vessel wall at both ends to ensure stability within the vessel and prevent type 1 endoleak. Second, within the limits imposed by appropriately sizing the ends at their landing zones, the FD size should be sized to optimize coverage over the aneurysm neck to better achieve thrombosis. To optimize device sizing, accurate measurements of the vessel to be treated are obligatory.
Precise measurement of intracranial vasculature can be challenging. As intracranial vessels course through the head, their distances from the X-ray source and detector change. This decreases accuracy and precision of angiographic measurements. [6] [7] [8] To mitigate these effects, standardized references with known dimensions, such as coins, washers, or fiducials, can be placed on patients' heads to allow more accurate calibration. [6] [7] [8] However, such techniques are still prone to inaccuracy because of differential distances between markers and the vessel of interest, although these distortions can be reduced with multiple markers. [6] [7] [8] To further address these limitations and achieve more accurate measurements, diagnostic angiography prior to FD treatment now routinely includes measurements obtained with the catheter visualized on the image so that the catheter can be used as a measurement standard to best measure the vessel to be treated. 9 However, the most accurately calibrated measurements will be unsatisfactory if the vessels are imaged while they are not in their native state. CIV is commonly encountered during neurointerventional techniques. 2 While it is often mild and of little clinical consequence, minor changes in measurements can have profound effects on FD performance. 2 Such CIV is routinely addressed with CCB infusion. 3, 4 In our practice, CIV is treated with 5 mg verapamil diluted in 10 ml saline and infused over three to five minutes. In addition to the benefit of selecting the most appropriately sized FD, CCB infusion can also reduce and prevent CIV incurred during FD deployment. If CIV occurs upstream to the device, it would reduce perfusion of the downstream parenchyma. CIV encountered at the site of treatment would limit expansion of the FD, reducing metal coverage over the aneurysm neck (Figure 2 ).
During the treatment of patients with FDs in our department, the effects of CIV on vessel measurements were noted anecdotally during several procedures. At times this was treated with CCB infusion, and repeat measurements were obtained. To evaluate the effect of CCB infusion on measurements and outcomes, we compared those with and without CCB infusion. Vessel measurements (proximal landing zone, distal landing zone, minimum diameter, maximum diameter) did vary between the two groups, but there was no statistical significance to these changes. However, there was an effect on subsequent OKM score on initial follow-up and aneurysm occlusion, with FDs deployed after measurements based on post-CCB infusion images performing more favorably. This suggests CCB infusion prior to angiography for measurements on which a device will be selected can promote the desired outcome of aneurysm occlusion.
While these findings suggest CCB infusion has a beneficial impact on sizing and subsequent performance of FDs, there are several limitations in this analysis. Patients evaluated were analyzed retrospectively, and the decision to employ CCB infusion was not made based on a standardized protocol. Additionally, while there were no differences in follow-up between the groups, post-treatment surveillance was not standardized. This analysis did not control for patients undergoing concomitant aneurysm coiling. This analysis did not find differences in aneurysm size or morphology, although aneurysms treated in our practice may differ from those treated elsewhere. Additionally, it is our practice to not treat with FD those aneurysms that have a major end artery arising from its dome or base. Also, it is our practice to perform percutaneous transluminal balloon angioplasty (PTA) or place another FD if apposition is inadequate or if there is inadequate neck coverage (>5 mm of stent deployed in the proximal and distal arterial segments). These results should not be applied to practices that employ different techniques. Device-related factors like bending and twisting or patient-specific factors like hemodynamics or fluid dynamics could affect deployment and subsequent occlusion; evaluation of such factors is beyond the scope of this analysis. Finally, aneurysm occlusion can be affected by changes in dual-antiplatelet therapy (DAPT). It is our practice to not alter DAPT until after the first follow-up angiogram, but it is possible that such changes could affect results. Therapeutic response to DAPT was not available at our center during the study period. To mitigate this potential bias, we examined both the OKM score at first follow-up, when DAPT should still be uniform, and overall occlusion, which could be affected by DAPT changes not reflected in the current analysis. The effect identified for both measures helps confirm the benefit of CCB infusion.
Conclusion
Optimization of device sizing is important to increase FD density over the aneurysm neck and promote thrombosis. To improve accuracy of measurements of parent vessels prior to device selection, CCB infusion can reduce the effects of mild vasospasm. In this study, subsequent aneurysm occlusion was more likely to occur following FD treatment when device size selection was based on measurements performed following CCB infusion. Further investigation is warranted to evaluate effects of CCB infusion and other factors affecting FD treatment of aneurysms.
